Geron Corporation
Financials
Valuation Metrics
Geron Corporation's Market Cap is $573M. At end of 2025 it was $881M. Ranked #2659 of 3,115 in US market (top 85%), #1146 of 1,472 on NASDAQ (top 78%), #208 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 78%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $573M | US#2,659/3,115 Sec#208/265 |
| Revenue | $205M | US#2,548/3,115 Sec#109/265 |
| Net Income | $-70M | US—/3,115 Sec—/265 |
| Total Assets | $519M | US#2,747/3,115 Sec#162/265 |
| Net Assets | $219M | US#2,642/3,115 Sec#181/265 |
| Employees | 258 | US#2,439/3,115 Sec#119/265 |
| Value | ||
| P/B | 2.62x | US#1,698/3,115 Sec#92/265 |
| P/S | 2.80x | US#1,729/3,115 Sec#48/265 |
| FCF Yield | -20.04% | US—/3,115 Sec—/265 |
| Profitability | ||
| ROE | -31.97% | US#2,574/3,115 Sec#117/265 |
| ROA | -13.47% | US#2,712/3,115 Sec#113/265 |
| Op. Margin | -18.29% | US#2,568/3,115 Sec#99/265 |
| Revenue Growth | 24.39% | US#544/3,115 Sec#67/265 |
| Financial Health | ||
| Debt Ratio | 137.41% | US#1,398/3,115 Sec#178/265 |
| Total Debt | $122M | US#2,377/3,115 Sec#109/265 |
| FCF | $-115M | US#2,660/3,115 Sec#157/265 |
| Cash | $63M | US#2,476/3,115 Sec#212/265 |
| Current Ratio | 6.92x | US#357/3,115 Sec#111/265 |
| Performance | ||
| 1Y Return | -27.98% | US#2,460/3,115 Sec#197/265 |
| 1M Return | -27.40% | US#2,940/3,115 Sec#240/265 |
| From 52W High | -55.57% | US#2,708/3,115 Sec#206/265 |
| 1Y MDD | -54.21% | US#2,413/3,115 Sec#163/265 |
| Trading | ||
| Volume | 17,364,363 shares | US#4/3,115 Sec#1/265 |
| Trading Value | $16M | US#1,017/3,115 Sec#60/265 |
| Per Share | ||
| EPS | $-0.11 | US—/3,115 Sec—/265 |
| BPS | $0.34 | US#2,769/3,115 Sec#222/265 |
Company Info
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.